Viking Therapeutics Sets Ambitious Clinical Trial Timeline for 2026

Viking Therapeutics completes enrollment for its pivotal VANQUISH-2 Phase 3 trial for VK2735, with multiple analyst upgrades and a robust late-stage pipeline driving market confidence.

Market confidence in Viking Therapeutics received a significant boost in late February when BTIG Research upgraded the biopharmaceutical company to a "Strong Buy" rating. This move was strategically timed, coinciding with the company's announcement that it had completed patient enrollment for its pivotal VANQUISH-2 Phase 3 clinical trial.

A Robust Late-Stage Pipeline Takes Shape

The company’s clinical development strategy is centered on VK2735, a dual GLP-1 and GIP receptor agonist. The recently filled VANQUISH-2 study is evaluating a subcutaneous formulation of this drug candidate. It involves approximately 1,000 adult participants who have been diagnosed with type 2 diabetes alongside obesity or overweight. This randomized, double-blind, and placebo-controlled trial is scheduled to run for 78 weeks.

With the earlier VANQUISH-1 trial having finished recruitment at the end of 2025, Viking Therapeutics now has both of its key registration studies on track. Top-line results from these trials are anticipated in 2027.

Looking ahead, CEO Brian Lian has outlined an aggressive plan for the remainder of 2026. The company intends to initiate a Phase 3 study for an oral formulation of VK2735 in the third quarter. Concurrently, initial data readouts are expected from a Phase 1 trial exploring various maintenance dosing regimens, which include monthly injections and a daily oral tablet. By the close of 2026, Viking aims to be managing four concurrent late-stage clinical studies.

Financial Health and Analyst Sentiment

The firm’s financial position appears solid, with a current ratio of 9.33 and a market capitalization hovering around $3.84 billion. This stability underpins the optimistic outlook shared by several equity research firms.

Analyst price targets reflect substantial confidence in the company's pipeline. Raymond James maintains its "Strong Buy" recommendation with a $118 target. Similarly, Jefferies and Truist Securities have reaffirmed their buy ratings, setting price objectives of $101 and $75 per share, respectively. The market responded positively to the VANQUISH-2 enrollment completion, with Viking's stock advancing approximately 3% on the day of the announcement.

In a separate corporate development, Vanguard reported an internal restructuring of its holdings on March 27. Due to a reclassification following SEC guidelines, various Vanguard subsidiaries will now report their positions in Viking Therapeutics separately rather than as a consolidated block. This is described as a purely administrative change with no material impact on the overall ownership structure.

The immediate focus for investors will be the planned launch of the oral VK2735 Phase 3 trial in Q3 2026, marking the next significant milestone for the clinical-stage company.